AMBROSE Cell Therapy’s Cycle of Care

The CEO of AMBROSE Cell Therapy, Matthew “Matt” Feshbach became interested in the possibility of stem cell therapies in 2009. Matthew Feshbach was able to start the company he had envisioned only after the Right to Try Act was passed in 2018, as it aligned to the technology, processes, and patient selection criteria he considered would most effectively serve the unmet need of no-option patients. The goal of the company is to mitigate symptoms and improve the functioning and quality of life in persons with chronic degenerative diseases through adult stem cell therapy.

AMBROSE Cell Therapy offers a personalized approach to each patient's care cycle, from the initial consultation with their MD patient consultant to the cell therapy treatment and advised aftercare programs. AMBROSE procedure protocols include tissue harvesting, direct injections (where indicated), and preparation and distribution of autologous adipose-derived stem and regenerative cells (ADRCs). Each tailored treatment plan is established with the specific needs of the patient in mind. For instance, certain illnesses, such as those affecting the lungs, kidney, liver, or brain, are best treated via intravenous injection. By contrast, a variety of autoimmune disorders, including rheumatoid arthritis, lupus, and psoriatic arthritis, as well as neuropathies, require localized injections.

To help boost the success rate of cell therapy, AMBROSE also recommends patients reduce excess stress and inflammation through prudent food choices, exercise, a supportive family and social environment, and lifestyle changes. This is because stress, inflammation, dysregulation of the immune system, and both acute and chronic disease have been scientifically demonstrated to be significantly connected.

What Is Cell Therapy?

Matthew “Matt” Feshbach is the founder and CEO of AMBROSE Cell Therapy. Established in 2018, AMBROSE Cell Therapy responded to a need for more technologically diverse treatment routes for no-option patients. Matthew Feshbach wanted the company's mission to be on improving symptoms, function, and quality of life in people with chronic degenerative diseases through adult stem cell therapy.

Cell therapy (CT) is a form of regenerative medicine seeing much interest in recent years. It encompasses a variety of processes and technologies that use human cells to repair damaged tissue in the body. For most of these procedures, laboratory researchers begin by cultivating stem cells and then differentiating them into specific cell types, such as heart muscle cells, blood cells, or nerve cells. Following that, the specialized cells can be put into a person. For instance, an individual with cardiac problems may have cells injected directly into the heart muscle. These transplanted healthy heart muscle cells could potentially contribute to the healing of damaged heart muscle.

Cell treatments may be used to treat cancer, autoimmune diseases, urinary issues, and infectious diseases. They have also shown promise in repairing damaged cartilage in joints and spinal cord injuries. Some forms of cell therapy may even assist patients with neurological diseases. 

Links Between Alzheimer's & Inflammation

Matthew “Matt” Feshbach, founder and CEO of Ambrose Cell Therapy, Inc., takes a personalized approach to health science through his organization. Targeting chronic systemic inflammation, Matthew Feshbach and his team have developed a protocol that spans tissue harvesting and direct injections, as well as adipose-derived stem and regenerative cell (ADRC) preparation and delivery that helps reverse the impacts of stress-related inflammation in patients.

An underlying basis for ADRC are the links discovered between inflammation, stress, and issues with the immune system. There are numerous examples of these correlations in the medical literature, across chronic and acute conditions. One major example is of brain-related diseases involving cognitive decline.A study cited in an article on the Ambrose Cell Therapy website (https://ambrosecelltherapy.com/improving-cell-therapy-outcomes/) spanned 300 patients, living independently and with mild-to-severe Alzheimer’s disease. After being evaluated for baseline cognitive function by a caretaker, they were tested for Tumor Necrosis Factor alpha (TNF-a), a pro-inflammatory cytokine.

From this point forward in the study, participants recorded additional acute stressful systemic inflammatory events as they occurred. These ranged from physical trauma to illness.TNF-a and cognitive function were retested at two, four, and six months, and compared with initial baseline levels. The findings indicated that chronic and acute systemic inflammation (measured in TNF-a levels) was strongly correlated with cognitive decline.